Claudia Vergelli

Dr. Claudia Vergelli

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MGMaria P. Giovannoni
Maria P. Giovannoni
CVClaudia Vergelli
Claudia Vergelli
CGcarla ghelardini
carla ghelardini
Nicoletta GaleottiNicoletta Galeotti
Nicoletta Galeotti
ABAlessandro Bartolini
Alessandro Bartolini
VPVittorio Dal Piaz
Vittorio Dal Piaz

29 July 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ACAgostino Cilibrizzi
Agostino Cilibrizzi
Mark QuinnMark Quinn
Mark Quinn
LKLiliya N. Kirpotina
Liliya N. Kirpotina
ISIgor A. Schepetkin
Igor A. Schepetkin
JHJeff Holderness
Jeff Holderness
MGMaria P. Giovannoni
Maria P. Giovannoni

12 July 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LCLetizia Crocetti
Letizia Crocetti
ISIgor A. Schepetkin
Igor A. Schepetkin
ACAgostino Cilibrizzi
Agostino Cilibrizzi
AGAlessia Graziano
Alessia Graziano
CVClaudia Vergelli
Claudia Vergelli
MGMaria P. Giovannoni
Maria P. Giovannoni

4 August 2008 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
MGMaria P. Giovannoni
Maria P. Giovannoni
CGcarla ghelardini
carla ghelardini
CVClaudia Vergelli
Claudia Vergelli
VPVittorio Dal Piaz
Vittorio Dal Piaz

1 June 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MGMaria P. Giovannoni
Maria P. Giovannoni
ISIgor A. Schepetkin
Igor A. Schepetkin
ACAgostino Cilibrizzi
Agostino Cilibrizzi
LCLetizia Crocetti
Letizia Crocetti
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
Mark QuinnMark Quinn
Mark Quinn
Formyl peptide receptors (FPRs) play an essential role in the regulation of endogenous inflammation and immunity. In the present studies, a large series of pyridazin-3(2H)-one derivatives bearing an arylacetamide chain at position 2 was synthesized and tested for FPR agonist activity. The pyridazin-3(2H)-one ring was confirmed to be an appropriate scaffold to support FPR agonist activity, and its modification at the 4 and 6 positions led to the identification of additional active agonists, which induced intracellular Ca(2+) flux in HL-60 cells transfected with either FPR1, FPR2, or FPR3. Seven formyl peptide receptor 1 (FPR1)-specific and several mixed FPR1/FPR2 dual agonists were identified with low micromolar EC50 values. Furthermore, these agonists also activated human neutrophils, inducing intracellular Ca(2+) flux and chemotaxis. Finally, molecular docking studies indicated that the most potent pyridazin-3(2H)-ones overlapped in their best docking poses with fMLF and WKYMVM peptides in the FPR1 and FPR2 ligand binding sites, respectively. Thus, pyridazinone-based compounds represent potential lead compounds for further development of selective and/or potent FPR agonists.

3 July 2015 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MGMaria P. Giovannoni
Maria P. Giovannoni
ISIgor A. Schepetkin
Igor A. Schepetkin
LCLetizia Crocetti
Letizia Crocetti
GCGiovanna Ciciani
Giovanna Ciciani
ACAgostino Cilibrizzi
Agostino Cilibrizzi
CVClaudia Vergelli
Claudia Vergelli
Compounds that can effectively inhibit the proteolytic activity of human neutrophil elastase (HNE) represent promising therapeutics for treatment of inflammatory diseases. We present here the synthesis, structure–activity relationship analysis, and biological evaluation of a new series of HNE inhibitors with a cinnoline scaffold. These compounds exhibited HNE inhibitory activity but had lower potency compared to N-benzoylindazoles previously reported by us. On the other hand, they exhibited increased stability in aqueous solution. The most potent compound, 18a, had a good balance between HNE inhibitory activity (IC50 value = 56 nM) and chemical stability (t1/2 = 114 min). Analysis of reaction kinetics revealed that these cinnoline derivatives were reversible competitive inhibitors of HNE. Furthermore, molecular docking studies of the active products into the HNE binding site revealed two types of HNE inhibitors: molecules with cinnolin-4(1H)-one scaffold, which were attacked by the HNE Ser195 hydroxyl group at the amido moiety, and cinnoline derivatives containing an ester function at C-4, which is the point of attack of Ser195.